Press releases

22 March 2023
Half-Year Report

15 March 2023
Update on SDC-1801

15 March 2023
Notice of Half-Year Results

06 March 2023
Update on SRA737

29 December 2022
Director/PDMR Shareholding

16 December 2022
Results of AGM

16 December 2022
AGM Statement

24 November 2022
Notice of AGM, Annual Report and Accounts

21 November 2022
Sareum Notes Publication of SRA737 Clinical Data

08 November 2022
Update on SDC-1801 CTA Application

24 October 2022
Final Results for the Year Ended 20 June 2022

12 October 2022
Update on SRA737

12 September 2022
Sareum notes FDA approval of first TYK2 Inhibitor

28 July 2022
CTA Application to MHRA and Corporate Update

04 July 2022
Sareum notes GSK's completed acquisition of Sierra

26 April 2022
Sareum to Present at BioTrinity 2022 Conference

13 April 2022
Sareum notes proposed acquisition of Sierra Oncology by GSK

11 April 2022
European patent granted for Sareum's SDC-1802

16 March 2022
Preclinical Toxicology Report Received

28 February 2022
Result of EGM

21 February 2022
Half-year Report

04 February 2022
Publication of Circular and Notice of General Meeting

28 January 2022
Issue of Warrants

17 December 2021
Subscription to raise £1.63m to progress SDC-1801

16 December 2021
Result of AGM

16 December 2021
AGM Statement

15 December 2021
Intention to Grant Notice - EU Patent for SDC-1802

07 December 2021
AGM Update

23 November 2021
Director/PDMR Shareholding

19 November 2021
Notice of AGM

03 November 2021
Exercise of Share Options and Director Dealings

29 October 2021
Appointment of Joint Corporate Broker

25 October 2021
Final Results

21 October 2021
Notice of Results

07 October 2021
US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor

29 September 2021
Reference to SRA737 Timeline at Cantor Conference

19 August 2021
Trading Statement

09 August 2021
Subscription to raise GBP 1,000,000

06 August 2021
SRA737 Update

30 July 2021
Patent Notice of Allowance for SDC-1802

19 July 2021
Subscription to raise £1,000,000

14 July 2021
Exercise of Warrants and Total Voting Rights

01 July 2021
Completed Covid-19 Research Project Delivers Encouraging Results

21 June 2021
Sareum to Present at BioTrinity 2021 Conference

15 June 2021
Subscription to raise £1,470,000

01 June 2021
Subscription to Raise £900,000

25 May 2021
Trading Update

13 May 2021
Exercise of Options and TVR

23 April 2021
Half-year Report

25 March 2021
Research Update

25 March 2021
Interim Results Extension

16 February 2021
Sareum Notes New UK Government Covid-19 Initiative

01 February 2021
Sareum to Present at the LSX World Congress 2021

26 January 2021
Sareum to Participate in the Edison Open House

08 January 2021
Update re: FLT3+Aurora Kinase Inhibitor Programme

07 January 2021
US Patent Grant for TYK2/JAK1 Anticancer Candidate

15 December 2020
Result of AGM

15 December 2020
AGM Statement

14 December 2020
Nature Article Highlights Role of TYK2 in Covid-19

03 December 2020
Covid-19 Research Grant Confirmed

19 November 2020
Notice of AGM

12 November 2020
Update on SRA737 Licensing Agreement

27 October 2020
Notification of Grant Award for Covid-19 Research

20 October 2020
Exercise of Share Options and Director Dealings

13 October 2020
Full Year Results Investor Presentation

13 October 2020
Final Results

08 October 2020
US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor

12 August 2020
Details of Investor Presentation

11 August 2020
Trading Statement

24 July 2020
Research Update

01 July 2020
Update on Deferred Salaries and Issue of Equity

03 June 2020
Successful Fundraising

02 June 2020
PrimaryBid.com Offer

02 June 2020
Placing to Raise £718,500

27 May 2020
Sareum to Present at BIO Digital 2020

01 May 2020
BioTrinity Presentation Available Online

28 April 2020
Company Presentation at BioTrinity

26 March 2020
Global Licensing of FLT3+Auroa Programme

26 March 2020
Half-year Report

12 March 2020
New SRA737 Combinations in Cancer

17 December 2019
Result of AGM

17 December 2019
AGM Statement

20 November 2019
Notice of AGM

05 November 2019
Sareum notes Sierra Oncology Q3 2019 Results

30 October 2019
Research Update - SDC-1802 Anti-Cancer Poster

17 October 2019
Research Update - AACR-NCI-EORTC abstract

15 October 2019
Final Results for the Year Ended 30 June 2019

07 October 2019
Notice of Full Year Results

27 September 2019
Research Update - TYK2/JAK1 Cancer Programme

27 August 2019
Trading Statement

16 August 2019
Change of Adviser

08 August 2019
Sareum notes Sierra Q2 results

30 July 2019
Additional disclosure concerning Michael Owen

28 June 2019
Additional Funds Raised

27 June 2019
Sierra Seeks Strategic Options for SRA737

26 June 2019
Successful Fundraising

25 June 2019
PrimaryBid.com Offer

25 June 2019
Placing to Progress TYK2/JAK1 Programmes

13 June 2019
Portfolio Update

03 June 2019
Key Takeaways from SRA737 Webcast at ASCO

03 June 2019
Positive SRA737 Data Reported at ASCO

16 May 2019
ASCO Abstracts for SRA737 Published

08 May 2019
Sareum notes Sierra Oncology Q1 2019 Results

30 April 2019
Sareum to Present at BioTrinity 2019 in London

23 April 2019
SRA737 Phase I/IIa data to be presented at ASCO

02 April 2019
Preclinical Data for SRA737 Presented at AACR 2019

12 March 2019
Issue of Options

04 March 2019
Half Yearly Results Ended 31 Dec 2018

28 February 2019
Sierra Oncology has reported its 2018 results

28 February 2019
New SRA737 preclin data to be presented at AACR

23 January 2019
Sierra Oncology to present SRA737 at DDR Tx Summit

18 December 2018
Results of AGM

18 December 2018
AGM Statement

30 November 2018
Preclinical Efficacy for Immunotherapy Combination

15 November 2018
Preclinical Data for SRA737 in Ovarian Cancer

14 November 2018
AGM NOTICE

13 November 2018
Directorate Change

08 November 2018
Sierra Oncology Q3 2018 Results

26 October 2018
Completion of Placing

01 October 2018
Final Results for the Year Ended 30 June 2018

26 September 2018
TYK2/JAK1 Selected for Certain Cancers

11 September 2018
Pre-Close Trading Statement

10 September 2018
Selection of TYK2/JAK1 for autoimmune diseases

09 August 2018
Sareum notes Sierra Oncology Q2 2018 Results

11 July 2018
Notification of PCA Shareholding

15 June 2018
Advisers

31 May 2018
Sareum regains rights to Aurora+FLT3 inhibitors

10 May 2018
SRA737 Trial Update in Sierra Oncology Q1 Results

17 April 2018
AACR 2018 Update

15 March 2018
Late-breaker abstract for SRA737 accepted for AACR

13 March 2018
Interim Results

27 February 2018
Sierra Oncology Expands SRA737 Development Programme

22 February 2018
Preclinical Synergy of SRA737 and PARP Inhibitor

13 February 2018
Notice of Interim Results

20 December 2017
Issue of Options

19 December 2017
Patent Grants in Japan & China for TYK2 Inhibitors

14 December 2017
Results of AGM

14 December 2017
AGM Statement

20 November 2017
Notice of AGM and Annual Report & Accounts

14 November 2017
Placing

31 October 2017
Sierra Reports Preclinical Data for Chk1 Inhibitor

19 October 2017
Final Results

09 October 2017
Sierra Oncology host KOL Meeting on 12 Oct in NY

18 September 2017
Sierra Oncology to host call on Chk1 inhibitor

22 August 2017
Pre-Close Trading Statement

19 June 2017
Sareum to Present at the International Cancer Cluster Showcase 2017

05 June 2017
Chk1 Clinical Trials Update

31 May 2017
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737

25 May 2017
Sierra Oncology to Present Chk1 Clinical Trial Enhancements at ASCO Annual Meeting

09 May 2017
Sareum to Present at BioTrinity 2017

09 March 2017
Director shareholding

20 February 2017
Half-year Results

09 January 2017
Milestone Payment from Chk1 Licence Agreement

06 December 2016
Directors’ Remuneration & General Meeting

29 November 2016
Sareum to Present at AACR-NCI-EORTC Conference

21 November 2016
Notice of AGM

02 November 2016
Final Results

24 October 2016
Successful Outcome from TYK2 Feasibility Study

17 October 2016
Japan and Singapore Patent Grants

27 September 2016
Licence agreement for Chk1 Inhibitor CCT245737

03 August 2016
China and Hong Kong Patent Grants for Sareum’s Aurora+FLT3 Kinase Inhibitors

28 July 2016
Movement in share price

23 May 2016
Clinical Trials of CHK1 Inhibitor CCT245737 to Open at the RMH

17 May 2016
Change of Director

05 April 2016
CHK1 Approved for Clinical Trials

24 March 2016
Placing

14 March 2016
Issue of Options

10 March 2016
Share Price Movement

24 February 2016
Research & Co-Development Collaborations Update

24 February 2016
Half Yearly Results for December 2015

01 February 2016
CHK1 Clinical Trial Application Submissions